Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.

The present invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the KCNT1 gene. The CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w/w). In an alternative embodiment the CBD may be in a synthetic form. In use the CBD may also be used concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Provided is an emulsion composition that allows a lipophilic ingredient to have high stability and high in vivo absorbability. The emulsion composition includes (a) a lipophilic ingredient, (b) a phospholipid, (c) a polyol, (d) water, (e) a sucrose fatty acid ester, and (f) a polyglycerol fatty acid ester. The content of the phospholipid (b) is from 2.0 to 15.0 parts by weight to 100 parts by weight of the total of the emulsion composition, and the weight ratio of the (f) polyglycerol fatty acid ester to the (e) sucrose fatty acid ester is from 0.1 to 0.9 parts by weight of the (f) polyglycerol fatty acid ester to 1 part by weight of the (e) sucrose fatty acid ester.

Provided is an emulsion composition that allows a lipophilic ingredient to have high stability and high in vivo absorbability. The emulsion composition includes (a) a lipophilic ingredient, (b) a phospholipid, (c) a polyol, (d) water, (e) a sucrose fatty acid ester, and (f) a polyglycerol fatty acid ester. The content of the phospholipid (b) is from 2.0 to 15.0 parts by weight to 100 parts by weight of the total of the emulsion composition, and the weight ratio of the (f) polyglycerol fatty acid ester to the (e) sucrose fatty acid ester is from 0.1 to 0.9 parts by weight of the (f) polyglycerol fatty acid ester to 1 part by weight of the (e) sucrose fatty acid ester.

Provided is an emulsion composition that allows a lipophilic ingredient to have high stability and high in vivo absorbability. The emulsion composition includes (a) a lipophilic ingredient, (b) a phospholipid, (c) a polyol, (d) water, (e) a sucrose fatty acid ester, and (f) a polyglycerol fatty acid ester. The content of the phospholipid (b) is from 2.0 to 15.0 parts by weight to 100 parts by weight of the total of the emulsion composition, and the weight ratio of the (f) polyglycerol fatty acid ester to the (e) sucrose fatty acid ester is from 0.1 to 0.9 parts by weight of the (f) polyglycerol fatty acid ester to 1 part by weight of the (e) sucrose fatty acid ester.